Losartan Potassium
Product Images NDC 64205-226

7 FDA label images from Readymeds · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 64205-226). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Readymeds, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing the percentage of patients with primary endpoint events over time between Losartan Potassium tablets and Atenolol. The x-axis represents study months from 0 to 66, and the y-axis represents percentage of patients with primary endpoint events up to 16%. Losartan Potassium shows a slightly lower event rate than Atenolol, with an adjusted risk reduction of 13% (p=0.021).*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph comparing the proportion of patients with salt retention or heart stroke over time (study months) between atenolol and losartan potassium tablets. The graph shows adjusted risk reduction for losartan potassium by 25%, with a p-value of 0.001, indicating statistical significance.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A figure showing primary endpoint events within demographic subgroups comparing Losartan Potassium tablets and Atenolol. It presents event rates for primary composite outcomes and fatal/non-fatal stroke, with hazard ratios and 95% confidence intervals, stratified by age, gender, race, ischemic heart disease, diabetes, and cardiovascular disease history.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph comparing the percentage of patients with an event over 48 months between two groups: one taking Losartan Potassium Tablets and the other a placebo. The graph shows risk reduction of 16.1% with a p-value of 0.022. The x-axis represents time in months, and the y-axis represents the percentage of patients with an event.*
FDA Label Image

Photo 1 (Photo 1)

Photo 1 (Photo 1)
Packaging label for ReadyMeds Losartan Potassium 100 mg tablets, quantity 30. The label displays the NDC number 64205-226-30, with fields for expiration date and lot number.*
FDA Label Image

Photo 2 (Photo 2)

Photo 2 (Photo 2)
Label from a ReadyMeds bottle of Losartan Potassium 50 mg tablets with a quantity of 30. The label includes the NDC number 64205-225-30 and fields for expiration date and lot number, though these are not filled in.*
FDA Label Image

Structure-losartan Potassium (Structure)

Structure-losartan Potassium (Structure)
Chemical structure diagram of losartan potassium, showing its molecular components and bonds, including the potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.